BCL2 and monocytic leukemia: The investigators proved that monocytic leukemia blasts lose expression of the Venetoclax target Bcl-2 while Myeloid cell leukemia‐1 (MCL-1) protein, an antiapoptotic member of the Bcl-2 family [82] expression is significantly higher in FAB-M5 patients.